Investigating the Potential of Cannabidiol as a Treatment for Alzheimer's Disease

Neuroinflammation plays a significant role in the progression of neurodegenerative diseases like Alzheimer's, as it causes damage to neurons and contributes to disease pathology. Recent research suggests that cannabidiol (CBD), a compound derived from cannabis known for its anti-inflammatory properties, might offer therapeutic benefits by targeting neuroinflammation.

A study published in the journal eNeuro by Babak Baban and colleagues from Augusta University examined whether inhaled CBD could modulate immune responses and reduce neuroinflammation in a mouse model of Alzheimer's disease. Their findings demonstrated that CBD treatment decreased the expression of key inflammatory regulators within the central nervous system, effectively lowering the levels of pro-inflammatory molecules. The team also identified specific immune regulators influenced by CBD, indicating a multi-faceted approach to immune modulation.

Traditionally, Alzheimer's treatment efforts have focused on amyloid plaques and tau tangles. However, this research underscores the importance of autoinflammation in the disease’s development. Baban notes that CBD not only calms immune system overactivation but also has previously been shown to aid in clearing plaques and tangles through distinct mechanisms. This multi-target approach highlights the promising potential of CBD as a comprehensive treatment option for Alzheimer's.

The findings suggest that integrating CBD into treatment strategies could help mitigate neuroinflammation, possibly slowing disease progression. As further research progresses, CBD may emerge as a valuable therapeutic agent in addressing both the immune response and hallmark pathologies of Alzheimer's. These insights pave the way for novel interventions that focus on immune regulation to combat neurodegeneration.

Source: https://medicalxpress.com/news/2025-10-exploring-therapeutic-potential-cannabidiol-alzheimer.html